Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2011
06/03/2011WO2010057710A3 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
06/03/2011WO2010052450A8 Tiotropium bromide having a low degree of crystallinity
06/03/2011WO2010033719A8 Treatment for leukemia and idiopathic aplastic anemia
06/03/2011WO2009016466A3 A process for the preparation of naratriptan hydrochloride
06/03/2011WO2008151415A8 Combination for treatment of diabetes mellitus
06/03/2011WO2006119507A3 Non-nucleotide composition and method for inhibiting platelet aggregation
06/03/2011CA2818891A1 Topical ibuprofen formulations
06/03/2011CA2783306A1 Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
06/03/2011CA2782280A1 Anti-tumor effect potentiator
06/03/2011CA2782266A1 Anticancer compounds and screening method
06/03/2011CA2782224A1 Azilsartan organic amine salts, preparation method and use thereof
06/03/2011CA2782207A1 Polymorphisms associated with parkinson's disease
06/03/2011CA2782179A1 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
06/03/2011CA2782163A1 Ondansetron orally disintegrating tablet compositions for prevention of nausea and vomiting
06/03/2011CA2782157A1 Lubricious aqueous composition
06/03/2011CA2782146A1 Small pyrimidine derivatives and methods of use thereof
06/03/2011CA2782127A1 Quinazolin-4(3a)-one derivatives and methods of use thereof
06/03/2011CA2782048A1 Use of a dipyridyl compound for treating rosacea
06/03/2011CA2782026A1 Pharmaceutical composition comprising mirna-100 and its use in the modulation of blood vessel growth and endothelial inflammation
06/03/2011CA2782024A1 Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
06/03/2011CA2782012A1 Triazolopyridine derivatives
06/03/2011CA2781915A1 Triazolopyridines
06/03/2011CA2781914A1 Substituted triazolopyridines
06/03/2011CA2781889A1 2-methylene-19,26-nor-(20s)-1.alpha.-hydroxyvitamin d3
06/03/2011CA2781820A1 Combination for the treatment of radiation- or chemotherapy-induced mucositis
06/03/2011CA2781818A1 Novel naphthyridine derivatives and the use thereof as kinase inhibitors
06/03/2011CA2781808A1 Novel polymorphic shapes of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl)carbamate
06/03/2011CA2781800A1 Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method
06/03/2011CA2781746A1 Inhibition of pancreatic lipase
06/03/2011CA2781744A1 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
06/03/2011CA2781726A1 Pharmaceutical compositions comprising sigma receptor ligands
06/03/2011CA2781676A1 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
06/03/2011CA2781660A1 Indole compound and pharmaceutical use thereof
06/03/2011CA2781627A1 6-substituted estradiol derivatives and methods of use
06/03/2011CA2781610A1 Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
06/03/2011CA2781572A1 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
06/03/2011CA2781571A1 Modulation of epidermal growth factor receptor ligands
06/03/2011CA2781451A1 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
06/03/2011CA2781436A1 Arachidonic acid analogs and methods for analgesic treatment using same
06/03/2011CA2781292A1 Novel spiropiperidine compounds
06/03/2011CA2781229A1 Use of an oleogel containing triterpene for healing wounds
06/03/2011CA2781082A1 Acrylic or methacrylic polymer including alpha-tocopherol grafts
06/03/2011CA2780998A1 Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
06/03/2011CA2780987A1 Novel compounds as receptor modulators with therapeutic utility
06/03/2011CA2780908A1 Novel compounds as receptor modulators with therapeutic utility
06/03/2011CA2780218A1 Morpholinothiazoles as alpha 7 positive allosteric modulators
06/03/2011CA2780138A1 Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
06/03/2011CA2780033A1 Sialochimeric compounds
06/03/2011CA2780025A1 Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride
06/03/2011CA2779875A1 Socs3 inhibition promotes cns neuron regeneration
06/03/2011CA2779404A1 Markers associated with ribavirin-induced anemia
06/03/2011CA2779089A1 Sultam derivatives
06/03/2011CA2778266A1 Potassium channel modulators
06/03/2011CA2776568A1 Sirna compounds comprising terminal substitutions
06/03/2011CA2776471A1 Surfactant-free, water-free, foamable compositions and breakable foams and their uses
06/03/2011CA2776361A1 Crystalline forms of substituted pyrazolopyrimidines
06/03/2011CA2776331A1 Liquid pharmaceutical compositions
06/03/2011CA2724303A1 Synergic combination of analgesic compounds
06/03/2011CA2687013A1 Method and composition for treatment and prevention of broad spectrum virus ailments
06/03/2011CA2687012A1 Compositions comprising igf1 agonists and uses thereof
06/02/2011US20110131671 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications
06/02/2011US20110131668 Improved gene silencing methods
06/02/2011US20110130710 Treatment of abnormal or excessive scars
06/02/2011US20110130707 Thiadiazole Compounds and Uses Thereof
06/02/2011US20110130704 Combination of a light ray and a lipase-bioconvertible compound for improving skin and/or hair appearance
06/02/2011US20110130698 Pressure-sensitive adhesive agent for skin, pressure-sensitive adhesive sheet for skin, and face plate of ostomy appliance
06/02/2011US20110130616 Magnetically Responsive Nanoparticle Therapeutic Constructs and Methods of Making and Using
06/02/2011US20110130570 Novel Form of S-Omeprazole
06/02/2011US20110130539 Method of Preparing Carboxylic Acid Functionalized Polymers
06/02/2011US20110130469 Compositions and methods relating to resveratrol
06/02/2011US20110130468 Hydroxylated tolans and related compounds in the treatment of a cancer
06/02/2011US20110130466 Use of rasagiline for the treatment of progressive supranuclear palsy
06/02/2011US20110130464 Combination Agent for Improving Carcass Performance in Finishing Pigs
06/02/2011US20110130463 Deuterium-enriched bupropion
06/02/2011US20110130462 Aqueous Organic Acidic Solution for Sterilization and Microbial Growth Inhibition
06/02/2011US20110130461 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
06/02/2011US20110130460 Increased creatine retention with soluble fibres
06/02/2011US20110130459 Composition for accelerated production of collagen
06/02/2011US20110130458 Krill oil process
06/02/2011US20110130457 Wax-Based Emulsion for the Treatment of Dry Eye Conditions
06/02/2011US20110130455 Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases
06/02/2011US20110130454 Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
06/02/2011US20110130453 Aminoalkylphenyl antagonists of prostaglandin d2 receptors
06/02/2011US20110130452 Store-operated calcium cellular assay
06/02/2011US20110130451 Method of treating dry eye disorders and uveitis
06/02/2011US20110130450 Pravastatin extraction
06/02/2011US20110130449 Assay for Monitoring Activity of Jmjd6
06/02/2011US20110130448 Functionalized phenolic esters and amides and polymers therefrom
06/02/2011US20110130447 Production of hop extracts having oestrogenic and antiproliferative bioactivity
06/02/2011US20110130446 Injectable taxane pharmaceutical composition
06/02/2011US20110130445 Substituted 3-phenylpropionic acids and the use thereof
06/02/2011US20110130444 Methods and compositions for targeted delivery of gene therapeutic vectors
06/02/2011US20110130443 Compositions And Methods For Inhibiting Expression Of Factor V Leiden Mutant Gene
06/02/2011US20110130442 Nucleic acid capable of controlling degranulation of mast cell
06/02/2011US20110130441 Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleosides
06/02/2011US20110130440 Non-natural ribonucleotides, and methods of use thereof
06/02/2011US20110130439 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
06/02/2011US20110130438 Aniline analogs as glycogen synthase activators
06/02/2011US20110130437 Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
06/02/2011US20110130436 Caspase inhibitors and uses thereof